Risk-adapted Therapy for Primary Acute Myeloid Leukemia

Leukemia, Myeloid, Acute Clinical Trial

Official title:

Risk-adapted Therapy for Primary Acute Myeloid Leukemia (AML) in Adult Patients up to 70 Years Old

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04687098
• Other study ID #: AML-12
• Status: Completed
• Phase: Phase 2
• Start date: February 1, 2012
• Est. completion date: November 10, 2022

Study information

• Verified date: June 2023
• Source: Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The AML-12 study investigates the efficacy and toxicity of standard induction chemotherapy with idarubicin and cytarabine (IC) with G-CSF priming followed by a risk-adapted post remission therapy for patients up to the age of 70 diagnosed with de novo acute myeloid leukemia (AML). Modifications from the previous protocol AML-03 (NCT01723657) include removal of etoposide in induction, limitation of the GCSF priming to the induction phase and categorization of post remission therapy (stem cell transplant or 2 high dose cytarabine consolidations) according to diagnostic genetics as well as post-remission clearance of measurable residual disease. The aims of these modifications are to improve the overall survival and leukemia free survival of acute myeloid leukemia patients with a risk-adapted approach.

Description:

Induction chemotherapy: Idarubicin (12mg/m2/day intravenous, days 1-3), Low-dose cytarabine (200mg/m2/day, intravenous in continuous infusion, days 1-7) and G-CSF priming 150mcg/m2/day, subcutaneous from day 0 to the last day of chemotherapy if white blood cell count (WBC) <30x10E9/L. This induction chemotherapy can be repeated twice in the case of partial response (PR) to achieve complete response (CR). Once CR is achieved (with one or two induction cycles), all patients receive a consolidation course with high-dose cytarabine (3000mg/m2/12h days 1, 3 and 5) and pegfilgrastim 6mg on day 6. After this, patients will be allocated to the different risk groups as follows: - Favorable risk group [patients with t(8;21)(q22;q22)/RUNX1/RUNX1T1, inv(16)(p12;q22) or t(16;16)/CBFB/MYH11; Intermediate risk cytogenetics (MRC 2010) and NPM1 mutation with FLT3 wild type or low ratio of FLT3 internal tandem duplication (ITD)/wild type (<0.5); or CEBPA biallelic mutation]. Patients in this group will receive 2 additional courses of consolidation therapy - Intermediate risk group [Intermediate risk cytogenetics (MRC 2010) without NPM1 mutations, FLT3-ITD, or CEBPA biallelic mutation]. Patients in this group receive an allogeneic stem cell transplant in first CR. Patients without an available donor can be autografted per center decision - Adverse risk group [Adverse risk cytogenetics (MRC 2010), intermediate cytogenetics with FLT3-ITD without NPM1 mutation or NPM1-FLT3-ITD high ratio or MLL rearrangement; any favorable or intermediate risk patients with positive MRD following 1 (intermediate) or 2 (favorable) consolidation courses]. Intention to treat of those patients is allogeneic stem cell transplant from any source.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1034
• Est. completion date: November 10, 2022
• Est. primary completion date: July 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 17 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with newly diagnosed AML, classified using the World Health Organization (WHO) 2017 criteria.
• Patients with 70 years old or younger.

Exclusion Criteria:

• Patients previously treated for the AML with chemotherapy different from hydroxyurea.
• Acute promyelocytic leukemia with t(15;17).
• Chronic myeloid leukemia in blastic phase.
• Secondary AML or therapy related AML.
• Presence of concomitant active neoplastic disease.
• Abnormal renal and hepatic functions with creatinin and/or bilirubin 2 times higher than the normal threshold, except when the alteration should be attributed to the leukemia.
• Patients with a cardiac ejection fraction below 45%, symptomatic cardiac deficiency or both.
• Patients with neurological or concomitant psychiatric disease.
• HIV infection.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• Idarubicin
12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.
• Ara-C
200mg/m2/day, intravenous at induction phase; days 1-7. - High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5.
• G-CSF
Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L. Administration at consolidation phase day 7.

Procedure:
• Allogeneic matched or unrelated donor transplant.
To be performed in patients in the intermediate or adverse risk groups.
• Autologous peripheral blood stem cell transplant
To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.
• Measurable residual disease
To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.

Locations

Country	Name	City	State
Spain	ICO Badalona-Hospital Universitari Germans Trias i Pujol	Badalona	Barcelona
Spain	Hospital Clinic Barcelona	Barcelona
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona
Spain	Hospital del Mar	Barcelona
Spain	Hospital Vall d'Hebron	Barcelona
Spain	ICO-Girona Hopital Universitari de Girona Dr. Josep Trueta	Girona
Spain	ICO Hospital Universitari de Bellvitge	Hospitalet de Llobregat	Barcelona
Spain	Hospital Universitari Arnau de Vilanova	Lleida
Spain	Hospital Universitario Virgen de la Victoria	Malaga
Spain	Hospital Universitari Son Espases	Palma de Mallorca	Mallorca
Spain	Hospital Universitari Son Llatzer	Palma de Mallorca	Mallorca
Spain	ICO Tarragona-Hospital Universitari Joan XXIII	Tarragona
Spain	Mutua de Terrassa	Terrassa
Spain	Hospital Verge de la Cinta	Tortosa	Tarragona
Spain	Hospital Clínico Universitario de Valencia	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete remission rate (CRR)	Analyze the efficacy and toxicity of the current doses of IC (Idarubicin and cytarabine) with G-CSF priming to achieve complete remission in patients tih AML up to 70yo.	2 months
Primary	Disease free survival (DFS)	Analyze the disease free survival in the whole cohort of AML patients.	4 years
Primary	Relapse rate (RR)	Analyze the relapse rate of all patients achieving remission with intensive induction followed by risk-adapted consolidation strategies.	4 years
Secondary	Feasibility of treatment completion	Increase the number of patients who complete all treatment phases	4 years
Secondary	Survival outcome analysis of the 3 risk-adapted categories (favourable, intermediate and adverse)	Evaluate the feasibility of the consolidation treatments in the different risk groups by comparison of overall survival (OS), RR and DFS.	4 years
Secondary	Feasibility of centralized monitoring of measurable residual disease (MRD)	Survival outcomes in positive vs negative MRD patients. Number of patients with modified risk due to positive MRD.	4 years
Secondary	Comparison of global outcomes with previous protocol (AML-03) and other published protocols.	Comparison of CRR, OS, RR and DFS	4 years